Browse the latest research summaries in the field of pharmacology for spinal cord injury patients and caregivers.
Showing 201-210 of 639 results
Frontiers in Pharmacology, 2024 • March 21, 2024
This study explores the analgesic effects of α2-adrenoceptor activation, particularly by dexmedetomidine (DEX), in the spinal cord, focusing on its molecular mechanisms. It utilizes behavioral, transc...
KEY FINDING: Spinal nerve injury changes the spinal transcriptome expression, with differential genes mainly related to calcium signaling and tissue metabolic pathways.
Heliyon, 2024 • April 1, 2024
This study investigates the effects of MLC901 on chronic phase SCI in Wistar rats, focusing on NG2 and caspase-3 expression, IL-10 levels, histopathology, and motor function. The findings demonstrate ...
KEY FINDING: MLC901 significantly decreased NG2 expression in the treatment group compared to the negative control group, suggesting a suppression of gliosis.
Drug Design, Development and Therapy, 2024 • April 18, 2024
This study explores the potential analgesic properties of obacunone (OB) in a CFA-induced inflammatory pain (IP) model in mice. The findings suggest that OB treatment facilitates a shift in microglia ...
KEY FINDING: OB treatment decreased PWF, paw thickness, M1 phenotype marker iNOS, CD86 significantly, while PWL, M2 phenotype marker Arg-1, IL-10, Nrf2, HO-1 increased significantly.
Frontiers in Pharmacology, 2024 • May 6, 2024
The blood-spinal cord barrier (BSCB) is disrupted within minutes of spinal cord injury, leading to increased permeability and secondary spinal cord injury, resulting in more severe neurological damage...
KEY FINDING: Spinal cord injury disrupts the blood-spinal cord barrier (BSCB), leading to secondary injuries and neurological damage.
Journal of Nanobiotechnology, 2024 • May 13, 2024
Central nervous system (CNS) diseases encompass spinal cord injuries, brain tumors, neurodegenerative diseases, and ischemic strokes, and are a leading cause of disability and death. Advances in biomi...
KEY FINDING: Biomimetic membrane materials can give NPs for drug delivery the privilege of “not being eaten” in vivo and can easily pass through the BBB.
International Journal of Medical Sciences, 2024 • May 13, 2024
This study investigated the effects of pregabalin on microglial differentiation in a rat model of neuropathic pain induced by sciatic nerve damage. The rats were treated with either pregabalin or a co...
KEY FINDING: Pregabalin treatment significantly reduced neuronal damage in both the brain and spinal cord of neuropathic pain rats compared to the control group.
Frontiers in Pharmacology, 2024 • May 20, 2024
This case report presents a patient with advanced HCC and spinal cord compression who was treated with a combination of QL1604 and bevacizumab, resulting in improved motor function, tumor shrinkage, a...
KEY FINDING: The patient's paralysis symptoms gradually improved, and the motor function of the lower limbs completely returned to normal after treatment with QL1604 and bevacizumab.
Front. Pharmacol., 2024 • May 22, 2024
This study provides proof of concept for an off-the-shelf NES cell-based therapy for SCI using cryopreserved doses derived from clinically relevant and GMP cleanroom-produced iPS cell lines. The resea...
KEY FINDING: Cryopreserved NES cells maintain high cell viability and retain their cell identity and differentiation capacity after thawing.
Bioinformation, 2024 • April 30, 2024
The study evaluated the efficacy of gabapentin, pregabalin, and amitriptyline in treating neuropathic pain. 270 patients were divided into three groups, each receiving one of the medications, and thei...
KEY FINDING: Gabapentin, pregabalin, and amitriptyline demonstrate similar effectiveness in alleviating neuropathic (NeP) pain.
Journal of Neuroimmune Pharmacology, 2024 • June 15, 2024
This study investigated the impact of minocycline on individual differences in pain-related affective disturbances in nerve-injured rats using a naturalistic foraging paradigm. The research focused on...
KEY FINDING: Minocycline completely prevented the emergence of an 'affected' subgroup of rats displaying disrupted foraging behaviours after nerve injury.